Worldwide Clinical Trials Adds AI-Driven Capability for Patient-Centric Enhanced Clinical Trial Optimization

Worldwide Clinical Trials, a global contract research organization (CRO), has added a cutting-edge artificial intelligence (AI) tool to enhance clinical trial optimization. This new service segments patient populations to identify those most likely to drive a positive trial outcome, leading to fewer required patients per trial, reduced timelines and costs, and ultimately increased success rates for sponsors.

Worldwide’s new service uses sophisticated AI algorithms, powered by NetraMark, to analyze complex data sets, including genomics, transcriptomics, and clinical scales, to identify key factors that optimize endpoint outcomes and pinpoint patients most likely to have a positive trial response. By identifying these key patient variables, Worldwide can provide sponsors fast, transparent, and clinically grounded insights that refine trial designs, reducing variability and optimizing response prediction.

“The introduction of this new service for our customers marks a significant advancement in our commitment to optimize clinical trials,” said Dave Bowser, Chief Operating Officer at Worldwide. “This service enhances trial efficiency and delivers regulatory-aligned insights from even the most complex datasets – leading to more successful trials while saving our customers valuable time and resources.”

Methodologies of this AI-driven capability align with regulatory expectations, ensuring robust and compliant clinical trial designs. The technology supports enrichment strategies by reducing variability, enhancing prognosis, and optimizing response prediction, focusing on patients more likely to respond positively to the drug treatment while excluding those prone to placebo effects.

"We’re proud to see our AI technology integrated into Worldwide Clinical Trials’ forward-thinking approach to clinical research. This reflects the shared vision between our teams to transform trial design through actionable intelligence and patient-centric insights. Worldwide’s deep therapeutic expertise and global footprint make them the ideal partner to bring the power of our technology to the pharmaceutical industry – enabling sponsors to run more efficient, precise, and successful trials that ultimately deliver better outcomes for patients around the world," said George Achilleos, CEO at NetraMark.

About Worldwide Clinical Trials:

Worldwide Clinical Trials (Worldwide) is a full-service global contract research organization (CRO) that works in partnership with biotechnology and pharmaceutical companies to create customized solutions that advance new medications – from discovery to reality. Worldwide’s capabilities include bioanalytical laboratory services, Phase I-IV clinical trials, and post-approval and real-world evidence studies – all powered by an accessible team of clinicians, scientists, and researchers who bring first-hand expertise and a collaborative, personalized approach to each clinical program. Worldwide is therapeutically focused on neuroscience, oncology, rare disease, and cardiometabolic and inflammatory disease. Its global footprint spans over 60 countries with more than 3,500 team members. For more information, visit www.worldwide.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250409854267/en/